Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC4761
- Development stage
- Preclinical
- Lead developer
- Obsidian Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GC4761 is a small molecule superoxide dismutase (SOD) mimic developed by Galera Therapeutics. It is designed to selectively convert superoxide radicals into hydrogen peroxide and oxygen, thereby reducing oxidative stress and mitigating tissue damage caused by ionizing radiation. In preclinical models of thoracic radiotherapy, GC4761 has demonstrated the ability to improve overall survival and reduce chronic cardiopulmonary complications, such as radiation pneumonitis, by addressing mitochondrial oxidative phosphorylation (OXPHOS) dysfunction. The compound acts as a catalyst to address the dose-limiting toxicities associated with upper body irradiation.
02
Targets
Misfolded SOD1
Beyond the preview
Go deeper on GC4761.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC4761.